Up a level |
Allen, Lucy, Allen, Lorna, Carr, Siobhan B, Davies, Gwyneth, Downey, Damian, Egan, Marie, Forton, Julian T, Gray, Robert, Haworth, Charles, Horsley, Alexander et al (show 3 more authors)
(2023)
Future therapies for cystic fibrosis.
Nature communications, 14 (1).
p. 693.
Southern, Kevin W ORCID: 0000-0001-6516-9083, Barben, Jürg, Goldring, Stephen, Kneen, Rachel, Southward, Suzanne, Rajeev, Yashavi, Davies, Jane C and Bush, Andrew
(2023)
Raised Intracranial Pressure in Three Children with Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor Modulator Therapy.
American journal of respiratory and critical care medicine, 208 (1).
pp. 103-105.
Mahenthiralingam, Eshwar, Weiser, Rebecca, Floto, R Andres, Davies, Jane C and Fothergill, Joanne L ORCID: 0000-0002-7012-1508
(2022)
Selection of Relevant Bacterial Strains for Novel Therapeutic Testing: a Guidance Document for Priority Cystic Fibrosis Lung Pathogens.
Current Clinical Microbiology Reports, 9 (4).
pp. 33-45.
Barben, Jurg, Castellani, Carlo, Munck, Anne, Davies, Jane C, De Winter-de Groot, Karin M, Gartner, Silvia, Kashirskaya, Nataliya, Linnane, Barry, Mayell, Sarah J, McColley, Susanna et al (show 8 more authors)
(2021)
Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID).
JOURNAL OF CYSTIC FIBROSIS, 20 (5).
pp. 810-819.
Bell, Scott C, Mall, Marcus A, Gutierrez, Hector, Macek, Milan, Madge, Susan, Davies, Jane C, Burgel, Pierre-Regis, Tullis, Elizabeth, Castaos, Claudio, Castellani, Carlo et al (show 28 more authors)
(2020)
The future of cystic fibrosis care: a global perspective.
LANCET RESPIRATORY MEDICINE, 8 (1).
pp. 65-124.
Rosenfeld, Margaret, Cunningham, Steve, Harris, William T, Lapey, Allen, Regelmann, Warren E, Sawicki, Gregory S, Southern, Kevin W ORCID: 0000-0001-6516-9083, Chilvers, Mark, Higgins, Mark, Tian, Simon et al (show 2 more authors)
(2019)
An open-label extension study of ivacaftor in children with CF and a <i>CFTR</i> gating mutation initiating treatment at age 2-5 years (KLIMB).
JOURNAL OF CYSTIC FIBROSIS, 18 (6).
pp. 838-843.